Purpose To analyze the prognostic impact of mutated KIT (mut KIT) in core-binding factor
acute myeloid leukemia (AML) with inv (16)(p13q22) and t (8; 21)(q22; q22). Patients and …

Selective inhibition of the BCR-ABL tyrosine kinase by imatinib (STI571, Glivec/Gleevec) is a
promising new therapeutic strategy in patients with chronic myelogenous leukemia (CML) …

Chronic myeloid leukemia (CML) is the paradigm for targeted cancer therapy. RT-qPCR is
the gold standard for monitoring response to tyrosine kinase-inhibitor (TKI) therapy based on …

Selective inhibition of the BCR-ABL tyrosine kinase by imatinib (Gleevec)(formerly STI571)
is a promising new therapeutic strategy in patients with chronic myelogenous leukemia …

Gene mutations independent of BCR:: ABL1 have been identified in newly diagnosed
patients with chronic myeloid leukemia (CML) in chronic phase, whereby mutations in …

To study clonal evolution in chronic myeloid leukemia (CML), we searched for BCR-ABL-
independent gene mutations in both Philadelphia chromosome (Ph)-negative and Ph …

This two-centre phase-II trial aimed at investigating the efficacy of imatinib in metastasised
melanoma patients in correlation to the tumour expression profile of the imatinib targets c-kit …

We sought to establish a rapid and reliable RT-PCR approach for detection and
quantification of BCR-ABL fusion transcripts using the LightCycler technology. This device …

The degree of tumor load reduction as measured by cytogenetic response is an important
prognostic factor for chronic myelogenous leukemia (CML) patients on therapy. We sought …

A substantial minority of patients with chronic myelogenous leukemia (CML) achieve a
complete response (CR) to treatment with interferon-(IFN), defined as the disappearance …